Ibrahim A, Bulstrode N W, Whitaker I S, Eastwood D M, Dunaway D, Ferretti P
Department of Plastic Surgery, Great Ormond Street Hospital For Children NHS Trust, London, UK; Stem Cell and Regenerative Medicine Section, UCL Great Ormond Street Hospital Institute of Child Health, University College London, UK; Reconstructive Surgery and Regenerative Medicine Research Group, The Welsh Centre for Burns & Plastic Surgery, Swansea, UK; European Centre of Nano Health, Swansea University Medical School, Swansea, UK.
Department of Plastic Surgery, Great Ormond Street Hospital For Children NHS Trust, London, UK; Stem Cell and Regenerative Medicine Section, UCL Great Ormond Street Hospital Institute of Child Health, University College London, UK.
Open Orthop J. 2016 Dec 30;10:849-861. doi: 10.2174/1874325001610010849. eCollection 2016.
Bone is the second most transplanted tissue and due to its complex structure, metabolic demands and various functions, current reconstructive options such as foreign body implants and autologous tissue transfer are limited in their ability to restore defects. Most tissue engineering approaches target osteoinduction of osteoprogenitor cells by modifying the extracellular environment, using scaffolds or targeting intracellular signaling mechanisms or commonly a combination of all of these. Whilst there is no consensus as to what is the optimal cell type or approach, nanotechnology has been proposed as a powerful tool to manipulate the biomolecular and physical environment to direct osteoprogenitor cells to induce bone formation.
Review of the published literature was undertaken to provide an overview of the use of nanotechnology to control osteoprogenitor differentiation and discuss the most recent developments, limitations and future directions.
Nanotechnology can be used to stimulate osteoprogenitor differentiation in a variety of way. We have principally classified research into nanotechnology for bone tissue engineering as generating biomimetic scaffolds, a vector to deliver genes or growth factors to cells or to alter the biophysical environment. A number of studies have shown promising results with regards to directing ostroprogenitor cell differentiation although limitations include a lack of data and incomplete characterization of engineered bone.
There is increasing evidence that nanotechnology can be used to direct the fate of osteoprogenitor and promote bone formation. Further analysis of the functional properties and long term survival in animal models is required to assess the maturity and clinical potential of this.
骨是第二大常用移植组织,由于其结构复杂、代谢需求多样且功能各异,目前诸如异物植入和自体组织移植等重建方法在修复缺损方面的能力有限。大多数组织工程方法旨在通过改变细胞外环境、使用支架或靶向细胞内信号传导机制(通常是所有这些方法的组合)来诱导骨祖细胞的骨诱导作用。虽然对于最佳细胞类型或方法尚无共识,但纳米技术已被提议作为一种强大的工具,用于操纵生物分子和物理环境以引导骨祖细胞诱导骨形成。
对已发表的文献进行综述,以概述纳米技术在控制骨祖细胞分化方面的应用,并讨论最新进展、局限性和未来方向。
纳米技术可通过多种方式刺激骨祖细胞分化。我们主要将骨组织工程纳米技术研究分为生成仿生支架、将基因或生长因子传递给细胞的载体或改变生物物理环境。尽管存在局限性,包括缺乏数据和对工程化骨的不完全表征,但多项研究在引导骨祖细胞分化方面显示出了有前景的结果。
越来越多的证据表明,纳米技术可用于引导骨祖细胞的命运并促进骨形成。需要对动物模型中的功能特性和长期存活进行进一步分析,以评估其成熟度和临床潜力。